Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x100px

Person › Details

Markus Enzelberger (Versant Ventures Ventures (Switzerland) GmbH)

Enzelberger, Markus (Versant Ventures 202003– EIR in Basel before MorphoSys 2002–202002)

	Organisation	Versant Ventures Ventures (Switzerland) GmbH
	Group	Versant Ventures
	Former/major organisation	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	MorphoSys (Group)
	Product	Ylanthia® antibody technology
	Product 2	HuCAL® Platinum

Record changed: 2022-08-11

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Markus Enzelberger

[1] MorphoSys AG. (11/20/19). "Press Release: Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure". Planegg....
[2] MorphoSys AG. (10/28/19). "Press Release: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility". Planegg & Mechelen....
[3] MorphoSys AG. (9/16/19). "Press Release: MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis". Planegg....
[4] MorphoSys AG. (2/27/19). "Press Release: MorphoSys Announces that Its Licensee Janssen Has Received U.S. FDA Approval for Tremfya One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis". Planegg....
[5] MorphoSys AG. (1/17/19). "Press Release: MorphoSys Announces that Its Licensee Janssen Has Expanded Clinical Development of Guselkumab (Tremfya) into Ulcerative Colitis". Planegg....
[6] MorphoSys AG. (11/26/18). "Press Release: MorphoSys Announces Approval of Tremfya (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis". Planegg....
[7] MorphoSys AG. (7/10/18). "Press Release: MorphoSys Announces Its Licensee Janssen Has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya (Guselkumab) in Crohn's Disease". Planegg....
[8] MorphoSys AG. (6/12/18). "Press Release: New Phase 3 Clinical Trials by MorphoSys’s Partner with Gantenerumab in Early Alzheimer's Disease now Underway". Planegg....
[9] MorphoSys AG. (4/6/18). "Press Release: MorphoSys Announces Approval of Tremfya (Guselkumab) for the Treatment of Moderate to Severe Forms of Psoriasis and Psoriatic Arthritis in Japan". Planegg....
[10] MorphoSys AG. (11/23/17). "Press Release: MorphoSys Announces that Its Licensee Janssen Has Received Approval for Tremfya (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis". Planegg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)